Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00812435 · ClinicalTrials.gov registry record · Phase 3
Eptifibatide and ST Segment Resolution Following Primary PCI
A Phase 3 study, sponsored by Medstar Health Research Institute.
- Terminated
- Registry status
- Phase 3
- Development phase
- 22
- Enrollment target
NCT00812435 is a Phase 3 study that was terminated before completion, run by Medstar Health Research Institute. The registered enrollment target is 22 participants.
The verdict
NCT00812435, a Phase 3 study, was terminated before completion, sponsored by Medstar Health Research Institute.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a prospective, open label, randomized trial of 100 patients who present to the cardiac catheterization laboratory with an ST Elevation Myocardial Infarction for primary PCI. Patients may receive up-front unfractionated heparin or low molecular weight heparin, but not glycoprotein IIb/IIIa inhibitors or thrombolytics. Patients will be consented prior to the diagnostic catheterization and will be randomized once the patient is deemed amenable to PCI to receive eptifibatide or no eptifibatide just prior to or at the time of primary angioplasty. Patients will be randomized in a 1:1 fashion. All patients will be assessed for the primary endpoint of ST resolution at 60 minutes post PCI and followed throughout the duration of the hospitalization and up to 30 days for secondary endpoint evaluation.
Interventions
- DRUG eptifibitide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00812435
The ClinicalTrials.gov registry entry for NCT00812435 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medstar Health Research Institute, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eptifibitide is the first listed.
NCT00812435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00812435 about?
NCT00812435 is a clinical study titled "Eptifibatide and ST Segment Resolution Following Primary PCI". This is a prospective, open label, randomized trial of 100 patients who present to the cardiac catheterization laboratory with an ST Elevation Myocardial Infarction for primary PCI. Patients may receive up-front unfractionated heparin or low molecular weight heparin, but not glycoprotein IIb/IIIa in...
What is the current status of trial NCT00812435?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 22 participants. The study started on 2007-08. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00812435?
The interventions under investigation include: eptifibitide (DRUG).
Who is sponsoring clinical trial NCT00812435?
This trial is sponsored by Medstar Health Research Institute, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.